Comparative Pharmacology
Head-to-head clinical analysis: RENOGRAFIN 60 versus RENOVIST II.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENOGRAFIN 60 versus RENOVIST II.
RENOGRAFIN-60 vs RENOVIST II
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RENOGRAFIN-60 (diatrizoate meglumine and diatrizoate sodium) is an ionic, high-osmolality, iodinated contrast agent. It enhances radiographic contrast by absorbing X-rays due to the high atomic number of iodine. It distributes into the intravascular space and is excreted primarily by the kidneys via glomerular filtration without significant tubular reabsorption or secretion.
RENOVIST II is a radiographic contrast agent that contains diatrizoate meglumine and diatrizoate sodium. It increases the radiopacity of vascular structures and organs by attenuating X-rays due to the high atomic number of iodine atoms in the molecule.
Intravenous: 50-100 mL of a 60% solution as a single dose for CT or angiography. Intra-arterial: 5-50 mL depending on vessel size. Maximum total dose: 3 mL/kg.
1-2 mL/kg IV bolus, not to exceed 150 mL total; may be repeated once if necessary.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours in normal renal function. Prolonged in renal impairment: up to 50 hours. Clinically significant for timing of contrast imaging and risk of contrast-induced nephropathy.
1.2 hours in patients with normal renal function; prolonged to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 95-100% (glomerular filtration, no tubular reabsorption). Biliary/Fecal: negligible.
Renal: 95% as unchanged drug via glomerular filtration; fecal: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent